Примери за използване на Biliary cirrhosis на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Hepatitis is medicinal, primary biliary cirrhosis- in complex treatment such drugs are applied.
Immunologic tests such as the antimitochondrial antibody may suggest the presence of primary biliary cirrhosis.
Primary Biliary Cholangitis(PBC; formerly known as primary biliary cirrhosis) is an important
Ursodiol is also used as a treatment for primary biliary cirrhosis(PBC), which is a liver disease that destroys the liver's bile ducts.
Diovan is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis(see sections 4.3 and 5.2).
such as primary biliary cirrhosis, primary sclerosing cholangitis
destruction of the small bile ducts within the liver(biliary cirrhosis) leading to the build up of bile in the liver(cholestasis).
98% of patients with primary biliary cirrhosis(PBC) have autoantibodies(antibodies to self)
A rare disease that is uncommonly associated with Sjogren's syndrome is primary biliary cirrhosis, an immune disease of the liver that leads to scarring of the liver tissue.
lack of intestinal absorption of the vitamin such as occurs in celiac sprue and primary biliary cirrhosis.
This medicine is used to treat adult patients with a type of liver disease known as primary biliary cholangitis(also known as primary biliary cirrhosis), either by itself
cholestatic or biliary cirrhosis), T 1/2 elongation by 50%
Diovan is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis(see sections 4.3,
OCALIVA is indicated for the treatment of primary biliary cholangitis(also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid(UDCA)
cholestatic, and biliary cirrhosis) given 10
cholestatic or biliary cirrhosis), the elongation of T 1/2 is 50%
hypercalcaemia Severe hepatic impairment, biliary cirrhosis and cholestasis.
Valsartan should not be administered in patients with severe hepatic impairment, cirrhosis or biliary obstruction.
it should be contraindicated in patients with severe liver diseases and“should not be administered in patients with severe hepatic impairment, cirrhosis or biliary obstruction.
the CHMP agreed that it should be contraindicated in patients with severe liver diseases and“should not be administered in patients with severe hepatic impairment, cirrhosis or biliary obstruction”.